ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v20i4.2603ppharm-2345Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCASE REPORTАнтилейкемические эффекты глюкокортикоидов при лечении острого лимфобластного лейкозаAntileukemic impact of glucocorticoid use in acute lymphoblastic leukaemia treatmenthttps://orcid.org/0000-0002-8350-4153ШервашидзеМ. А.ShervashidzeMeri A.

Шервашидзе Мери Алексеевна.

Москва

MD.

Moscow

shervashidze85@gmail.comhttps://orcid.org/0009-0007-2171-1951СмирноваД. С.SmirnovaDaria S.

Смирнова Дарья Сергеевна.

Москва

MD.

Moscow

stratostat55@gmail.comhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievTimur T.

Валиев Тимур Теймуразович - доктор медицинских наук, заведующий детским отделением химиотерапии гемобластозов НИИ ДОиГ им. акад. РАМН Л.А. Дурнова ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава.

115478, Москва, Каширское ш., д. 24

тел.: +7 (499) 324-42-87

MD, PhD.

24 Kashirskoe shosse, Moscow, 115478

tel.: +7 (905) 797-70-06

timurvaliev@mail.ruhttps://orcid.org/0000-0002-2945-284XКиргизовК. И.KirgizovKirill I.

Киргизов Кирилл Игоревич – кандидат медицинских наук.

Москва

MD, PhD.

Moscow

k.kirgizov@ronc.ruhttps://orcid.org/0000-0001-6131-1783ВарфоломееваС. Р.VarfolomeevaSvetlana R.

Варфоломеева Светлана Рафаэлевна – доктор медицинских наук, профессор.

Москва

MD, PhD, Professor.

Moscow

s.varfolomeeva@ronc.ruФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of OncologyRussian Federation202322082023204303308Copyright © Шервашидзе М.А., Смирнова Д.С., Валиев Т.Т., Киргизов К.И., Варфоломеева С.Р., 20232023Шервашидзе М.А., Смирнова Д.С., Валиев Т.Т., Киргизов К.И., Варфоломеева С.Р.Shervashidze M.A., Smirnova D.S., Valiev T.T., Kirgizov K.I., Varfolomeeva S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2345

Глюкокортикоиды (ГК) на протяжении нескольких десятилетий используются в клинической медицине в качестве противовоспалительных, иммуносупрессивных и противоопухолевых агентов благодаря их свойству ингибировать клеточный цикл и индуцировать апоптоз, однако точный механизм их действия не изучен до конца. Ключевую роль препараты ГК играют в лечении острого лимфобластного лейкоза, занимая одну из базовых позиций на этапе индукции и реиндукции ремиссии. Ответ опухолевого клона на ГК детерминирует группу риска и прогноз заболевания. Ряд механизмов антилейкемического действия ГК и факторов резистентности к ним будут рассмотрены в настоящей статье.

Glucocorticoids (GC) are used as anti-inflammatory, immunosupressive and anti-tumor agents for several decades due to their ability to cell cycle inhibition and apoptosis induction but mechanism of action is not fully explored. Glucocorticoids play one of the key roles in acute lymphoblastic leukaemia treatment and are at the forefront in induction and reinduction phases. The response of tumor clone to GC determines a risk group and prognosis. A number of mechanisms of antileukemic action and resistance factors will be describe in this article.

глюкокортикоидыантилейкемический эффектострый лимфобластный лейкозлечениеglucocorticoidantileukemic effectacute lymphoblastic leukemiatreatmentОтсутствует.Not specified.ReferencesHunger SP. Glucocorticoid selection for pediatric ALL. Blood. 2016;127(17):2049-2051. doi: https://doi.org/10.1182/blood-2016-02-701664Hunger SP. Glucocorticoid selection for pediatric ALL. Blood. 2016;127(17):2049-2051. doi: https://doi.org/10.1182/blood-2016-02-701664Jing D, Bhadri VA, Beck D, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood. 2015;125(2):273-283. doi: https://doi.org/10.1182/blood-2014-05-576470Jing D, Bhadri VA, Beck D, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood. 2015;125(2):273-283. doi: https://doi.org/10.1182/blood-2014-05-576470Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096-1106. doi: https://doi.org/10.1016/S1470-2045(10)70114-5Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096-1106. doi: https://doi.org/10.1016/S1470-2045(10)70114-5Gruber G, Carlet M, Turtscher E, et al. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia. 2009;23(4):820-823. doi: https://doi.org/10.1038/leu.2008.360Gruber G, Carlet M, Turtscher E, et al. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia. 2009;23(4):820-823. doi: https://doi.org/10.1038/leu.2008.360Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2009;300(1-2):7-16. doi: https://doi.org/10.1016/j.mce.2008.10.001Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2009;300(1-2):7-16. doi: https://doi.org/10.1016/j.mce.2008.10.001Carlet M, Janjetovic K, Rainer J, et al. Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells. BMC Cancer. 2010;10:638. doi: https://doi.org/10.1186/1471-2407-10-638Carlet M, Janjetovic K, Rainer J, et al. Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells. BMC Cancer. 2010;10:638. doi: https://doi.org/10.1186/1471-2407-10-638Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42-54. doi: https://doi.org/10.1016/j.tem.2017.10.010Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42-54. doi: https://doi.org/10.1016/j.tem.2017.10.010Catts VS, Farnsworth ML, Haber M, et al. High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance. Leukemia. 2001;15(6):929-935. doi: https://doi.org/10.1038/sj.leu.2402128Catts VS, Farnsworth ML, Haber M, et al. High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance. Leukemia. 2001;15(6):929-935. doi: https://doi.org/10.1038/sj.leu.2402128Sun F, Zhou JL, Wei SX, et al. Glucocorticoids induce osteonecrosis of the femoral head in rats via PI3K/AKT/FOXO1 signaling pathway. PeerJ. 2022;10:e13319. doi: https://doi.org/10.7717/peerj.13319Sun F, Zhou JL, Wei SX, et al. Glucocorticoids induce osteonecrosis of the femoral head in rats via PI3K/AKT/FOXO1 signaling pathway. PeerJ. 2022;10:e13319. doi: https://doi.org/10.7717/peerj.13319Schmidt S, Rainer J, Ploner C, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11(Suppl 1):S45-S55. doi: https://doi.org/10.1038/sj.cdd.4401456Schmidt S, Rainer J, Ploner C, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11(Suppl 1):S45-S55. doi: https://doi.org/10.1038/sj.cdd.4401456Ausserlechner MJ, Obexer P, Bock G, et al. Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. Cell Death Differ. 2004;11(2):165-174. doi: https://doi.org/10.1038/sj.cdd.44013281Ausserlechner MJ, Obexer P, Bock G, et al. Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. Cell Death Differ. 2004;11(2):165-174. doi: https://doi.org/10.1038/sj.cdd.44013281Mansha M, Carlet M, Ploner C, et al. Functional analyses of Src-like adaptor (SLA), a glucocorticoid-regulated gene in acute lymphoblastic leukemia. Leuk Res. 2010;34(4):529-534. doi: https://doi.org/10.1016/j.leukres.2009.06.029Mansha M, Carlet M, Ploner C, et al. Functional analyses of Src-like adaptor (SLA), a glucocorticoid-regulated gene in acute lymphoblastic leukemia. Leuk Res. 2010;34(4):529-534. doi: https://doi.org/10.1016/j.leukres.2009.06.029Gardner JP, Zhang L. Glucocorticoid modulation of Ca2+ homeostasis in human B lymphoblasts. J Physiol. 1999;514(Pt 2):385-396. doi: https://doi.org/10.1111/j.1469-7793.1999.385ae.xGardner JP, Zhang L. Glucocorticoid modulation of Ca2+ homeostasis in human B lymphoblasts. J Physiol. 1999;514(Pt 2):385-396. doi: https://doi.org/10.1111/j.1469-7793.1999.385ae.xDurmaz B, Bagca BG, Cogulu O, et al. Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia. Biomed Res Int. 2021;2021:3207328. doi: https://doi.org/10.1155/2021/3207328Durmaz B, Bagca BG, Cogulu O, et al. Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia. Biomed Res Int. 2021;2021:3207328. doi: https://doi.org/10.1155/2021/3207328Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002;9(1):6-19. doi: https://doi.org/10.1038/sj.cdd.4400969Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002;9(1):6-19. doi: https://doi.org/10.1038/sj.cdd.4400969Schmidt S, Rainer J, Riml S, et al. Identification of glucocorticoidresponse genes in children with acute lymphoblastic leukemia. Blood. 2006;107(5):2061-2069. doi: https://doi.org/10.1182/blood-2005-07-2853Schmidt S, Rainer J, Riml S, et al. Identification of glucocorticoidresponse genes in children with acute lymphoblastic leukemia. Blood. 2006;107(5):2061-2069. doi: https://doi.org/10.1182/blood-2005-07-2853Orkin SH, Fisher DE, Ginsburg D, et al. Nathan and Oskis Hematology and Oncology of Infancy and Childhood. 8th edition. Elsevier Saunders, 2015, 2752pOrkin SH, Fisher DE, Ginsburg D, et al. Nathan and Oskis Hematology and Oncology of Infancy and Childhood. 8th edition. Elsevier Saunders, 2015, 2752p

The authors declare that there are no conflicts of interest present.